Pneumococcal vaccine protects children from otitis

The frequent ear infections suffered by some infants during the first two years of life can be difficult to treat. Most are caused by Streptococcus pneumoniae, also responsible for chest infections in adults and for which there is already a vaccine. A team from the National Public Health Institute, Helsinki, Finland tested the efficacy of the new conjugate pneumococcal vaccine in children and found that it can also be effective in the prevention of ear infections (N Engl J Med 2001, 344:403-409)

By | February 13, 2001

The frequent ear infections suffered by some infants during the first two years of life can be difficult to treat. Most are caused by Streptococcus pneumoniae, also responsible for chest infections in adults and for which there is already a vaccine. A team from the National Public Health Institute, Helsinki, Finland tested the efficacy of the new conjugate pneumococcal vaccine in children and found that it can also be effective in the prevention of ear infections (N Engl J Med 2001, 344:403-409).

Juhani Eskola and colleagues investigated 1662 infants in a randomised, double-blind trial of the heptavalent pneumococcal polysaccharide conjugate vaccine CRM197. The children received either the pneumococcal vaccine or a hepatitis B vaccine as a control at 2, 4, 6 and 12 months of age; they were followed up until the age of two years.

The vaccine reduced by 57% the number of episodes of acute otitis media caused by the serotypes included in it. The number of otitis episodes attributed to serotypes that are cross-reactive with those in the vaccine was reduced by 51%. But the number of episodes due to all other serotypes increased by 33%.

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Authors Peeved by APA’s Article Takedown Pilot
  3. Athletes’ Microbiomes Differ from Nonathletes
  4. Was a Drop in CRISPR Firms’ Stock Warranted?
AAAS